China-headquartered drug developer Adagene has raised $69 million in a Series D funding round led by US global growth equity firm General Atlantic, per a company statement.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
